Finance Monthly, a global publication providing news, analysis and features on all the latest headlines within the financial sector in US, Europe and Asia nominates APIM Therapeutics's CEO Kostas Alevizopoulos for a 2013 CEO Award. A copy of the CEO Awards 2013 issue of Finance Monthly featuring an interview of K. Alevizopoulos is provided here (see page 15).
PLoS ONE publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper provides key data on the mechanism of action of ATX-101, the current company lead drug candidate, in various cellular models as well as proof-of-efficacy data in disease-relevant multiple myeloma ex vivo and in vivo models. Overall, ATX-101 shows strong efficacy in the absence of toxicity in agreement with the innovative therapeutic concept of the company. A pdf copy of the publication is provided here.
APIM Therapeutics appoints Professor Per Uno Malmström (Department of Urology, Uppsala University, Sweden) at its scientific advisory board. Prof. Malmström, a recognized Key Opinion Leader in bladder cancer and Chairman of the Nordic Bladder Cancer Group, is expected to catalyze future clinical development of APIM Therepeutics's lead compound ATX-101 having significant experience in early phase I/II clinical trials for this indication.
Kostas Alevizopoulos, APIM Therapeutics's Chief Executive Officer gives an interview to Finance Monthly, an electronic journal focusing on private equity, acquisitions, funding and investments. A copy of the article is available at this address (see page 32).
NTNU Professor Marit Otterlei, APIM Therapeutics's Chief Scientific Officer and primary inventor gives an interview to Norwegian daily journal Sunnmørsposten about APIM's anti-cancer development program. A copy of the article (in Norwegian) is available at this address.
Professor M. Otterlei, APIM Therapeutics's Chief Scientific Officer and primary inventor, and her collaborators at the Norwegian University of Science and Technology (NTNU) publish a scientific paper at PLOS One showing functional implication of XPA and PCNA in Nucleotide Excision Repair (NER) mechanisms associated with the replisome. The publication provides validation of the APIM motif, a newly identified AlkB homolog 2 PCNA interacting motif mediating interactions of a large number of proteins involved in DNA repair, cell cycle control and apoptosis with PCNA upon stress. A full copy of the article can be downloaded here.
Daily Norwegian journal Adressa interviews NTNU Professor and Chief Scientific Officer of APIM Therapeutics, M. Otterlei, about the promising anti-cancer properties of APIM's drug candidates. A copy of the article (in Norwegian) is available at this address.
APIM Therapeutics announced today conclusion of a financing round led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed, Birk Venture and Ro Invest. Financing will be used to further advance the preclinical development of APIM Therapeutics' anti-cancer lead compound ATX-101. For more information, please visit the following web site link: http://www.prnewswire.com/news-releases/apim-therapeutics-closes-a-financing-round-174553791.html.
Biocentury, a leading biotechnology publication, features APIM Therapeutics in an article published on-line on April 23rd. The article discusses in detail the novel therapeutic approach of the company and its implications for the development of novel cancer therapies. A full copy of the article can be downloaded here.
APIM Therapeutics joins the Oslo Cancer Cluster, an oncology research cluster comprising academic institutions, biotech and pharma companies, support groups, financial institutions and regional development players in the field of cancer R & D.
Biotech Finances, a French electronic magazine specializing in reporting global biotech financing news publishes article on APIM Therapeutics (Issue 527, November 21; see www.biotech-finances.com). A copy of the article (in French) can be downloaded here.
APIM Therapeutics announced today conclusion of a third seed follow-up financing round led by Scandinavian investment companies Birk Venture and Ro Invest in syndication with Sarsia Seed, a seed stage investor that has already led two investment transactions in APIM Therapeutics. Financing will be used to further advance the preclinical development of APIM Therapeutics' anti-cancer lead compound in selected tumor indications including blood cancer and solid tumors. For more information, please visit the following web site link.
APIM Therapeutics announced today conclusion of a second seed follow up financing round by Sarsia Seed, a Norwegian seed stage life science fund. Financing will be used to advance the preclinical investigation of APIM Therapeutics' lead compound in further cancer in vivo studies, predominantly in Myeloma and Acute Myeloid Leukemia. For more information, please visit: http://www.prnewswire.co.uk/cgi/news/release?id=315415
APIM Therapeutics announced today that Sarsia Seed, a Norwegian seed stage life science fund, has invested NOK 3.5 million (€ 440.000) in APIM Therapeutics. The company, a spin-out from the Norwegian University of Science and Technology (NTNU), is developing novel peptide drugs which have the potential to improve clinical outcomes achieved with a large group of existing first line chemotherapeutics.